# T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

> **NCT07152782** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 202 (estimated)

## Conditions studied

- Breast Cancer With Brain Metastasis
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT07152782
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2027-11
- **Final completion:** 2029-11
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152782, "T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07152782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*